Events - Spark Newswire

2 minute read

Immutep To Present Phase II TACTI-002 Data At SITC 2021

Today, 4:12 AM

Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is

IMMP

2 minute read

Rubius Therapeutics Reports Preclinical Data For RTX-224 Will Be Presented At Society For Immunotherapy Of Cancer Meeting Nov. 12 At 7 a.m. EST

By Benzinga Newsdesk

Today, 4:12 AM

Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell

RUBY

2 minute read

Codiak To Present Preclinical Data Demonstrating New Potential Therapeutic Applications Of Engineered Exosomes At Society For Immunotherapy Of Cancer (SITC) Annual Meeting

By Benzinga Newsdesk

Today, 4:12 AM

Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that three posters

CDAK

3 minute read

Events
News

Immuneering Reports Will Present Preclinical Data Across Several Poster Presentations At AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Oct. 7-10

By Benzinga Newsdesk

Today, 4:12 AM

Preclinical Data Demonstrates Broad Antitumor Activity of IMM-1-104 Across RAS and RAF Mutant Tumors and Highlights Mechanistic Aspects of its Dual MEK Inhibition Company to Host Key Opinion Leader Event on October 12,

IMRX

2 minute read

Events
News

BrainStorm Cell Therapeutics To Present Phase 2 Data Results At Congress of the European Committee for Treatment and Research in Multiple Sclerosis Oct. 14 At 10:45 a.m. EDT

By Benzinga Newsdesk

Today, 4:12 AM

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that a scientific abstract titled "Phase 2 Safety and Efficacy Study

BCLI

2 minute read

Decibel Therapeutics Announces Publication Of Foundational Study Of Noise-related Inner Ear Damage

By Benzinga Newsdesk

Today, 4:12 AM

Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that findings from

DBTX

1 minute read

IMV’s DPX Delivery Technology To Be Showcased In 2 e-Posters At AACR-NCI-EORTC Conference On Molecular Targets And Cancer Therapeutics

By Benzinga Newsdesk

Today, 4:12 AM

IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced that two abstracts featuring two DPX-based

IMV

4 minute read

Events
News

Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Poster Presentation at AACR-NCI-EORTC 2021

By Michael Horton

Today, 4:12 AM

Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will present preclinical data in a poster at the AACR-NCI-EORTC Virtual International

KRON

1 minute read

Events
News

Immunome To Present Preclinical Data On Anti IL-38 Antibody Program At The American Association For Cancer Research NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics

By Benzinga Newsdesk

Today, 4:12 AM

Immunome, Inc. (NASDAQ:IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that it will be making an oral poster

IMNM

2 minute read

Salarius Pharmaceuticals And Nationwide Children’s Hospital Announce Poster Presentation At 2021 AACR-NCI-EORTC Virtual International Conference On Molecular Targets And Cancer Therapeutics

By Benzinga Newsdesk

Today, 4:12 AM

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, and Nationwide

SLRX